Keith FlahertyDevelopmental Therapeutics, Massachusetts General Hospital Cancer Center, Boston, MA, USA F1000 Faculty Member (since 16 October 2007)
BIOGRAPHYDr. Flaherty received a Bachelor of Science from Yale University and medical degree from Johns Hopkins University. He trained in internal medicine at Brigham and Women's Hospital and completed a fellowship in medical oncology at the University of Pennsylvania.
He joined the faculty in the School of Medicine at the University of Pennsylvania as an Assistant Professor of Medicine and member of the Developmental Therapeutics Program in the Abramson Cancer Center in 2002. In 2009, Dr. Flaherty moved to Massachusetts General Hospital and Harvard Medical School to serve as the Director of Developmental Therapeutics for the MGH Cancer Center. He was awarded a K23 grant from the NCI to investigate the inhibition of angiogenesis with targeted therapy combinations in melanoma and renal cell carcinoma. In addition to being principal investigator of numerous first-in-human clinical trials with novel targeted therapies, he is the principal investigator of two national, cooperative group trials: E2603, a phase III trial comparing sorafenib, carboplatin and paclitaxel to carboplatin and paclitaxel alone in patients with metastatic melanoma and E2804, a randomized phase II trial comparing combinations of anti-angiogenic agents in metastatic renal cell carcinoma. He served as principal investigator for the first-in-human clinical trials of the first prospectively developed selective BRAF inhibitors, RAF-265 and PLX4032. PLX4032 has emerged as the most active single-agent therapy ever evaluated in metastatic melanoma patients, and is rapidly being tested in a phase III trial of which Dr. Flaherty serves as co-principal investigator. He is internationally known for expertise in clinical and translational research directed against signal transduction pathways in melanoma.
Viewing Article Recommendations by Faculty Members requires a subscription.
If you believe you should be able to view this content, contact us at firstname.lastname@example.org.
F1000 Medicine Reports 2011 3:(8) (01 Apr 2011)
Keith Flaherty has been added to your "Faculty I'm Following" page in MyF1000
Follow/Unfollow any Faculty via their recommendations, biography pages, or MyF1000